These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

916 related items for PubMed ID: 26447477

  • 1. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
    Perazzoli G, Prados J, Ortiz R, Caba O, Cabeza L, Berdasco M, Gónzalez B, Melguizo C.
    PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
    [Abstract] [Full Text] [Related]

  • 2. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
    Zhao Y, Xiao Z, Chen W, Yang J, Li T, Fan B.
    Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
    [Abstract] [Full Text] [Related]

  • 3. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
    Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A.
    J Transl Med; 2012 Dec 17; 10():250. PubMed ID: 23245659
    [Abstract] [Full Text] [Related]

  • 4. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H, Lin H, Zhang X, Li J.
    Oncol Rep; 2012 Jun 17; 27(6):2050-6. PubMed ID: 22426504
    [Abstract] [Full Text] [Related]

  • 5. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.
    J Clin Invest; 2012 Jan 17; 122(1):253-66. PubMed ID: 22156195
    [Abstract] [Full Text] [Related]

  • 6. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W, Liu X, Wang H, Fan Y, Lian S, Yang X, Wang X, Guo G, Li Q, Wang S.
    Mol Med Rep; 2015 Jun 17; 11(6):4165-73. PubMed ID: 25625235
    [Abstract] [Full Text] [Related]

  • 7. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
    Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN.
    Neuro Oncol; 2009 Jun 17; 11(3):281-91. PubMed ID: 18952979
    [Abstract] [Full Text] [Related]

  • 8. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
    Clark PA, Gaal JT, Strebe JK, Pasch CA, Deming DA, Kuo JS, Robins HI.
    J Clin Neurosci; 2017 Feb 17; 36():120-124. PubMed ID: 27865821
    [Abstract] [Full Text] [Related]

  • 9. Temozolomide: mechanisms of action, repair and resistance.
    Zhang J, Stevens MF, Bradshaw TD.
    Curr Mol Pharmacol; 2012 Jan 17; 5(1):102-14. PubMed ID: 22122467
    [Abstract] [Full Text] [Related]

  • 10. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
    Leshchenko VV, Kuo PY, Jiang Z, Thirukonda VK, Parekh S.
    Clin Cancer Res; 2014 Jan 15; 20(2):382-92. PubMed ID: 24178621
    [Abstract] [Full Text] [Related]

  • 11. Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.
    Tezcan G, Tunca B, Demirci H, Bekar A, Taskapilioglu MO, Kocaeli H, Egeli U, Cecener G, Tolunay S, Vatan O.
    Nutr Cancer; 2017 Jan 15; 69(6):873-880. PubMed ID: 28718668
    [Abstract] [Full Text] [Related]

  • 12. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
    Moen EL, Stark AL, Zhang W, Dolan ME, Godley LA.
    Mol Cancer Ther; 2014 May 15; 13(5):1334-44. PubMed ID: 24568970
    [Abstract] [Full Text] [Related]

  • 13. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguroğlu A, Castresana JS, Ugur HC.
    Tumour Biol; 2013 Jun 15; 34(3):1935-47. PubMed ID: 23519841
    [Abstract] [Full Text] [Related]

  • 14. MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.
    Vlachostergios PJ, Hatzidaki E, Papandreou CN.
    Neurol Res; 2013 Oct 15; 35(8):879-82. PubMed ID: 23561593
    [Abstract] [Full Text] [Related]

  • 15. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
    Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN.
    J Natl Cancer Inst; 2016 May 15; 108(5):. PubMed ID: 26615020
    [Abstract] [Full Text] [Related]

  • 16. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA.
    Neuro Oncol; 2021 Jun 01; 23(6):920-931. PubMed ID: 33433610
    [Abstract] [Full Text] [Related]

  • 17. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
    Tso JL, Yang S, Menjivar JC, Yamada K, Zhang Y, Hong I, Bui Y, Stream A, McBride WH, Liau LM, Nelson SF, Cloughesy TF, Yong WH, Lai A, Tso CL.
    Mol Cancer; 2015 Nov 06; 14():189. PubMed ID: 26546412
    [Abstract] [Full Text] [Related]

  • 18. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
    van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ, Sminia P.
    Br J Cancer; 2010 Jun 29; 103(1):29-35. PubMed ID: 20517307
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
    Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN.
    Clin Cancer Res; 2012 Aug 01; 18(15):4070-9. PubMed ID: 22675172
    [Abstract] [Full Text] [Related]

  • 20. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
    Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R.
    Int J Oncol; 2015 Aug 01; 47(2):417-28. PubMed ID: 26035292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.